A startup founded by University of Toronto alumni has won Silicon Valley buy-in for its novel approach to AI-assisted drug development - resurrecting therapies the pharma industry had given up on, the. . .
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.